Document Type : Original Research


1 Department of Pathology, Hamadan University of Medical Sciences, Hamadan, Iran

2 Department of Community Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

3 Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran


Background & Objective: Female breast cancer is one of the most prevalent malignancies among women. The critical step in managing breast cancer is to diagnose it accurately. Hence, peripheral blood-based tests are one of the most favorable and less invasive methods to study. Recent studies investigated and evaluated the inflammation parameters such as neutrophil: lymphocyte ratio (NLR), the platelet: lymphocyte ratio (PLR), and the C-reactive protein (CRP) levels. The elevation in mentioned parameters was proposed as a key factor in cancer progression. The main goal of this study was to investigate the association of NLR, PLR, and CRP levels in patients with breast lesions.
Methods: The NLR, PLR, and CRP levels were calculated from 200 female patients with either benign or malignant lesions.
Results: The cut-off values of NLR, PLR, and CRP were 1.24, 96, and 10.36 mg/L, respectively. A significant difference in NLR (P<0.001), PLR (P<0.001), and CRP levels (P<0.001) were observed between the two major studied cohorts.
Conclusion: Elevated NLR, PLR, and CRP levels could predict the presence of malignancy. In addition to the low cost and properties of the mentioned methods, utilization of this data could facilitate and improve clinical decision-making for treatment. 


Main Subjects

  1. Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Mac Bride MB, Dilaveri CA, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc. 2014;89(4):536-47. [DOI:10.1016/j.mayocp.2014.02.004] [PMID]
  2. Masciadri N, Ferranti C. Benign breast lesions: Ultrasound. J Ultrasound. 2011;14(2):55-65. [DOI:10.1016/j.jus.2011.03.002] [PMID] [PMCID]
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI:10.3322/caac.21660] [PMID]
  4. Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 2018;233 (7):5200-13. [DOI:10.1002/jcp.26379] [PMID]
  5. Stoiber D, Assinger A. Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells. 2020;9(4). [PMID] [PMCID] [DOI:10.3390/cells9040855]
  6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. [DOI:10.1016/j.cell.2010.01.025] [PMID] [PMCID]
  7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. [DOI:10.1016/j.cell.2011.02.013] [PMID]
  8. Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med. 2017;7(7). [PMID] [PMCID] [DOI:10.1101/cshperspect.a026781]
  9. Kim J, Bae JS. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016;2016:6058147. [DOI:10.1155/2016/6058147] [PMID] [PMCID]
  10. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663):1532-5. [DOI:10.1126/science.1092385] [PMID]
  11. Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. The Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis. Front Immunol. 2020;11 (1749):1749. [DOI:10.3389/fimmu.2020.01749] [PMID] [PMCID]
  12. Palacios-Acedo AL, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. Front Immunol. 2019;10:1805. [PMID] [PMCID] [DOI:10.3389/fimmu.2019.01805]
  13. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155-70. [DOI:10.3109/10408363.2011.599831] [PMID]
  14. Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, et al. incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. Cancer Lett. 2006;240(1):143-7. [DOI:10.1016/j.canlet.2005.09.004] [PMID]
  15. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-63. [DOI:10.2217/fon.09.136] [PMID]
  16. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30. [DOI:10.1016/j.critrevonc.2013.03.010] [PMID]
  17. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176-81. [DOI:10.1016/j.lungcan.2017.07.024] [PMID]
  18. Liu C, Li X. Stage-Dependent Changes in Albumin, NLR, PLR, and AFR are Correlated with Shorter Survival in Patients with Gastric Cancer. Clin Lab. 2019;65(9). [DOI:10.7754/Clin.Lab.2019.190132]
  19. Wang H, Ding Y, Li N, Wu L, Gao Y, Xiao C, et al. Prognostic Value of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Combined Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Stage IV Advanced Gastric Cancer. Front Oncol. 2020;10(841):841. [DOI:10.3389/fonc.2020.00841] [PMID] [PMCID]
  20. Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151-e8. [DOI:10.1016/j.clgc.2018.07.027] [PMID]
  21. Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33-8. [DOI:10.1016/j.breast.2018.12.014] [PMID]
  22. Kim JY, Jung EJ, Kim JM, Lee HS, Kwag SJ, Park JH, et al. Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer. 2020;20(1):1206. [DOI:10.1186/s12885-020-07700-9] [PMID] [PMCID]
  23. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. Int J Breast Cancer. 2015;2015:145647. [DOI:10.1155/2015/145647] [PMID] [PMCID]
  24. Wei B, Yao M, Xing C, Wang W, Yao J, Hong Y, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. OncoTargets Ther. 2016;9:5567-75. [DOI:10.2147/OTT.S108419] [PMID] [PMCID]
  25. Wang L. Early Diagnosis of Breast Cancer. Sensors (Basel). 2017;17(7). [DOI:10.3390/s17071572] [PMID] [PMCID]
  26. Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018;18(8):485-99. [DOI:10.1038/s41568-018-0010-y] [PMID]
  27. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5): 646-74. [DOI:10.1016/j.cell.2011.02.013] [PMID]
  28. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454 (7203):436-44. [DOI:10.1038/nature07205] [PMID]
  29. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. [DOI:10.1038/nature01322] [PMID] [PMCID]
  30. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70. [DOI:10.1126/science.1203486] [PMID]
  31. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938-45. [DOI:10.1038/nm.3909] [PMID] [PMCID]
  32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-54. [DOI:10.1056/NEJM199902113400607] [PMID]
  33. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14.
  34. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217-24. [DOI:10.1245/s10434-011-1814-0] [PMID]
  35. Zhang M, Huang XZ, Song YX, Gao P, Sun JX, Wang ZN. High Platelet-to-Lymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Breast Cancer: A Meta-Analysis. BioMed Res Int. 2017;2017: 9503025. [DOI:10.1155/2017/9503025] [PMID] [PMCID]
  36. Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S, et al. Prognostic role of C-reactive protein in breast cancer: a systematic review and meta-analysis. Int J Biol Markers. 2011;26(4):209-15. [DOI:10.5301/JBM.2011.8872] [PMID]
  37. Huszno J, Kolosza Z. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients. Oncol Lett. 2019;18(6):6275-83. [DOI:10.3892/ol.2019.10966] [PMCID]
  38. Ramos-Esquivel A, Rodriguez-Porras L, Porras J. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in non-metastatic breast cancer patients from a Hispanic population. Breast Dis. 2017;37(1):1-6. [DOI:10.3233/BD-160251] [PMID]
  39. Takeuchi H, Kawanaka H, Fukuyama S, Kubo N, Hiroshige S, Yano T. Comparison of the prognostic values of preoperative inflammation-based parameters in patients with breast cancer. PLoS One. 2017;12(5):e0177137. [PMID] [PMCID] [DOI:10.1371/journal.pone.0177137]
  40. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta. 2014;1845(2): 182-201. [DOI:10.1016/j.bbcan.2014.01.004] [PMID]